JP2017502686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502686A5 JP2017502686A5 JP2016553231A JP2016553231A JP2017502686A5 JP 2017502686 A5 JP2017502686 A5 JP 2017502686A5 JP 2016553231 A JP2016553231 A JP 2016553231A JP 2016553231 A JP2016553231 A JP 2016553231A JP 2017502686 A5 JP2017502686 A5 JP 2017502686A5
- Authority
- JP
- Japan
- Prior art keywords
- genbank accession
- accession number
- gene expression
- value
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims 44
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 27
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 27
- 239000000523 sample Substances 0.000 claims 27
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 238000002560 therapeutic procedure Methods 0.000 claims 15
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 10
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 10
- 238000001574 biopsy Methods 0.000 claims 5
- 210000001280 germinal center Anatomy 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 238000010322 bone marrow transplantation Methods 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 238000011476 stem cell transplantation Methods 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 102100033900 Ankyrin repeat and SOCS box protein 13 Human genes 0.000 claims 2
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 claims 2
- 102100039299 Cyclic AMP-responsive element-binding protein 3-like protein 2 Human genes 0.000 claims 2
- 102100029713 E3 ubiquitin-protein ligase TRIM56 Human genes 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 101000925512 Homo sapiens Ankyrin repeat and SOCS box protein 13 Proteins 0.000 claims 2
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 claims 2
- 101000745624 Homo sapiens Cyclic AMP-responsive element-binding protein 3-like protein 2 Proteins 0.000 claims 2
- 101000795363 Homo sapiens E3 ubiquitin-protein ligase TRIM56 Proteins 0.000 claims 2
- 101000852593 Homo sapiens Inositol-trisphosphate 3-kinase B Proteins 0.000 claims 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 2
- 101001005101 Homo sapiens LIM domain-containing protein 1 Proteins 0.000 claims 2
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims 2
- 101000593398 Homo sapiens Myb-related protein A Proteins 0.000 claims 2
- 101000998596 Homo sapiens NADH-cytochrome b5 reductase 2 Proteins 0.000 claims 2
- 101000609379 Homo sapiens Pre-mRNA-splicing factor ISY1 homolog Proteins 0.000 claims 2
- 101000743768 Homo sapiens R3H domain-containing protein 1 Proteins 0.000 claims 2
- 101001099877 Homo sapiens Ras-related protein Rab-43 Proteins 0.000 claims 2
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 claims 2
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 claims 2
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 claims 2
- 101000693262 Homo sapiens Sphingosine 1-phosphate receptor 2 Proteins 0.000 claims 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 claims 2
- 101000803751 Homo sapiens WD repeat-containing protein 55 Proteins 0.000 claims 2
- 102100036404 Inositol-trisphosphate 3-kinase B Human genes 0.000 claims 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 2
- 102100026033 LIM domain-containing protein 1 Human genes 0.000 claims 2
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims 2
- 102100034711 Myb-related protein A Human genes 0.000 claims 2
- 102100033168 NADH-cytochrome b5 reductase 2 Human genes 0.000 claims 2
- 102100038382 R3H domain-containing protein 1 Human genes 0.000 claims 2
- 102100038479 Ras-related protein Rab-43 Human genes 0.000 claims 2
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 claims 2
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 claims 2
- 102100030420 Serpin A9 Human genes 0.000 claims 2
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 claims 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 2
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 claims 2
- 102100035132 WD repeat-containing protein 55 Human genes 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900553P | 2013-11-06 | 2013-11-06 | |
| US61/900,553 | 2013-11-06 | ||
| PCT/US2014/064161 WO2015069790A1 (en) | 2013-11-06 | 2014-11-05 | Method for subtyping lymphoma types by means expression profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018323A Division JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502686A JP2017502686A (ja) | 2017-01-26 |
| JP2017502686A5 true JP2017502686A5 (enExample) | 2017-12-14 |
| JP6657105B2 JP6657105B2 (ja) | 2020-03-04 |
Family
ID=51987470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553231A Active JP6657105B2 (ja) | 2013-11-06 | 2014-11-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
| JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10607717B2 (enExample) |
| EP (2) | EP3066215B1 (enExample) |
| JP (2) | JP6657105B2 (enExample) |
| KR (1) | KR102357699B1 (enExample) |
| CN (1) | CN106232831B (enExample) |
| AU (1) | AU2014346788B8 (enExample) |
| CA (1) | CA2929826C (enExample) |
| ES (2) | ES2923942T3 (enExample) |
| WO (1) | WO2015069790A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202008673WA (en) | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| US10609336B2 (en) * | 2015-04-16 | 2020-03-31 | Offender Smartphone Monitoring, LLC | Monitoring process |
| CN109516981B (zh) | 2015-07-13 | 2019-10-22 | 大连万春布林医药有限公司 | 普那布林组合物 |
| AU2016331058B2 (en) | 2015-09-29 | 2022-04-07 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse large b-cell lymphoma (dlbcl) |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| WO2017184861A1 (en) | 2016-04-20 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Evaluation of mantle cell lymphoma and methods related thereto |
| CA3023841C (en) | 2016-05-13 | 2021-10-19 | F. Hoffmann-La Roche Ag | Methods and compositions for classifying dlbcl |
| KR20240091084A (ko) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
| WO2018089442A2 (en) * | 2016-11-09 | 2018-05-17 | Intel IP Corporation | Ue and devices for detach handling |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| IL268305B2 (en) | 2017-02-01 | 2024-08-01 | Beyondspring Pharmaceuticals Inc | Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced |
| EP3638814B8 (en) | 2017-06-14 | 2023-06-21 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Method for determining lymphoma type |
| CN111032692A (zh) * | 2017-08-08 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗 |
| JP7517983B2 (ja) * | 2017-11-20 | 2024-07-17 | ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク | 非常に低レベルのｃｄ１９を発現する骨髄腫細胞を除去するｃｄ１９ｃａｒｔ細胞 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| KR102834361B1 (ko) | 2017-12-01 | 2025-07-17 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도 |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| CA3087106A1 (en) | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
| WO2020028563A1 (en) * | 2018-08-01 | 2020-02-06 | Genentech, Inc. | Prediction and characterization of dlbcl cell of origin subtypes |
| JP2021533800A (ja) | 2018-08-21 | 2021-12-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用 |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3867404B1 (en) * | 2018-10-15 | 2025-09-17 | Provincial Health Services Authority | Gene expression profiles for b-cell lymphoma and uses thereof |
| CN113661253B (zh) * | 2018-11-14 | 2024-03-12 | 大连万春布林医药有限公司 | 微管蛋白结合剂治疗癌症的方法 |
| KR20210144863A (ko) * | 2019-03-28 | 2021-11-30 | 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) | B-세포 비-호지킨 림프종의 분류 |
| CN111850114A (zh) * | 2019-04-25 | 2020-10-30 | 上海交通大学医学院附属瑞金医院 | 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群，其试剂盒及分析方法 |
| CN113614230B (zh) * | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2021013805A1 (en) * | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | Systems and methods for cell of origin determination from variant calling data |
| EP4013494A1 (en) | 2019-08-12 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| CN111621565B (zh) * | 2020-05-07 | 2023-12-15 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
| CN111785370B (zh) * | 2020-07-01 | 2024-05-17 | 医渡云（北京）技术有限公司 | 病历数据处理方法及装置、计算机存储介质、电子设备 |
| BR112023000125A2 (pt) * | 2020-07-08 | 2023-04-11 | Dayton Therapeutics Ag | Satraplatina para uso no tratamento de neoplasias linfoides |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| CN113186289B (zh) * | 2021-05-12 | 2023-02-24 | 清华大学深圳国际研究生院 | lncRNA在肾癌尿液筛查和肾癌治疗中的应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| DE69132905T2 (de) | 1990-12-06 | 2002-08-01 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Detektion von Nukleinsäuresequenzen |
| CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| AU675054B2 (en) | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| JP2000512744A (ja) | 1996-05-16 | 2000-09-26 | アフィメトリックス，インコーポレイテッド | 標識材料を検出するシステムおよび方法 |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
| US6020198A (en) | 1998-09-25 | 2000-02-01 | Isis Pharmaceuticals Inc. | Antisense modulation of RIP-1 expression |
| US7105293B2 (en) | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| US20030194701A1 (en) | 2000-11-20 | 2003-10-16 | Golub Todd R. | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| EP1436283B1 (en) | 2001-09-21 | 2008-01-23 | Boryung Pharmaceutical Co., Ltd. | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
| US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| MXPA05005923A (es) | 2002-12-06 | 2005-09-21 | Millennium Pharm Inc | Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma. |
| JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| US20110152115A1 (en) | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| ATE514434T1 (de) | 2004-02-25 | 2011-07-15 | Dana Farber Cancer Inst Inc | Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum |
| EP1805197A1 (en) | 2004-09-27 | 2007-07-11 | Med Biogene Inc | Hematological cancer profiling system |
| WO2006110264A2 (en) | 2005-03-16 | 2006-10-19 | Sidney Kimmel Cancer Center | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| BRPI0820707A2 (pt) * | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| US20110195426A1 (en) | 2009-07-16 | 2011-08-11 | The General Hospital Corporation | Nucleic acids analysis |
| EP2604704B1 (en) | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| CA2726811C (en) | 2008-06-06 | 2019-11-26 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large b cell lymphoma |
| ES2352777B1 (es) | 2009-07-31 | 2012-01-23 | Hospital Clinic De Barcelona | Metodo y kit para el pronostico del linfoma de celulas del manto |
| CA2778953C (en) * | 2009-11-13 | 2020-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| WO2011097476A1 (en) | 2010-02-04 | 2011-08-11 | Indiana University Research And Technology Corporation | 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen |
| EP2569335B1 (en) * | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| NZ604040A (en) * | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| US20120258878A1 (en) | 2010-08-04 | 2012-10-11 | Med Biogene Inc. | Prognostic gene signatures for non-small cell lung cancer |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| EP2788535A4 (en) | 2011-12-09 | 2015-07-29 | British Columbia Cancer Agency | PREDICTION OF A PROGNOSIS IN CLASSIC HODGKIN LYMPHOMA |
| US9493775B2 (en) * | 2012-02-10 | 2016-11-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
| US9803245B2 (en) | 2012-03-14 | 2017-10-31 | University Health Network | Signature for predicting clinical outcome in human HER2+ breast cancer |
| WO2013188600A1 (en) | 2012-06-12 | 2013-12-19 | Washington University | Copy number aberration driven endocrine response gene signature |
| WO2014197936A1 (en) | 2013-06-14 | 2014-12-18 | The State Of Queensland Acting Through Its Department Of Health | Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
-
2014
- 2014-11-05 ES ES19170689T patent/ES2923942T3/es active Active
- 2014-11-05 US US15/035,101 patent/US10607717B2/en active Active
- 2014-11-05 AU AU2014346788A patent/AU2014346788B8/en active Active
- 2014-11-05 CN CN201480072382.7A patent/CN106232831B/zh active Active
- 2014-11-05 KR KR1020167014876A patent/KR102357699B1/ko active Active
- 2014-11-05 ES ES14803288T patent/ES2738289T3/es active Active
- 2014-11-05 CA CA2929826A patent/CA2929826C/en active Active
- 2014-11-05 JP JP2016553231A patent/JP6657105B2/ja active Active
- 2014-11-05 EP EP14803288.1A patent/EP3066215B1/en active Active
- 2014-11-05 EP EP19170689.4A patent/EP3594359B1/en active Active
- 2014-11-05 WO PCT/US2014/064161 patent/WO2015069790A1/en not_active Ceased
-
2020
- 2020-01-17 US US16/746,347 patent/US11574704B2/en active Active
- 2020-02-05 JP JP2020018323A patent/JP7016129B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502686A5 (enExample) | ||
| Roudko et al. | Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors | |
| Lapuente-Santana et al. | Interpretable systems biomarkers predict response to immune-checkpoint inhibitors | |
| Buccitelli et al. | Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation | |
| Green et al. | Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation | |
| Eleveld et al. | RAS–MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma | |
| Jinesh et al. | Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers | |
| Granados et al. | MHC I–associated peptides preferentially derive from transcripts bearing miRNA response elements | |
| Kowalski et al. | Genetic variants of CDH23 associated with noise-induced hearing loss | |
| Krivega et al. | Consequences of chromosome gain: A new view on trisomy syndromes | |
| Song et al. | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients | |
| Zhou et al. | Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma | |
| US20140357660A1 (en) | Gene expression signatures of neoplasm responsiveness to therapy | |
| Adams et al. | Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW | |
| Feilotter et al. | BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development | |
| EP3149209B1 (en) | Methods for typing of lung cancer | |
| Zhao et al. | Cancer cells enter an adaptive persistence to survive radiotherapy and repopulate tumor | |
| JP2016515390A5 (enExample) | ||
| Douglas et al. | Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer | |
| CA3177706A1 (en) | System and method for gene expression and tissue of origin inference from cell-free dna | |
| de Oliveira Costa et al. | Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade? | |
| Lynnhtun et al. | Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis | |
| JP2018518980A5 (enExample) | ||
| Bemanian et al. | Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer | |
| Miliotis et al. | Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci |